Development of Ovarian Cancer in Ultrasound Indeterminate Ovarian Lesions: Incidence and Tumor Type


Ashley Cahoon, Elizabeth Maddox, Katherine Maturen, Jessica Robbins, Elizabeth Sadowski, Alexander Blaty, Ashish Wasnik, Lisa Barroilhet, Laura Huffman, Krupa Patel-Lippmann, Viktoriya Paroder













The authors have no disclosures




Study Goal

 The goal of this study is to determine the incidence of ovarian cancer in sonographically indeterminate cystic ovarian lesions



Background


- Ovarian cancer has the highest mortality of any of the gynecologic malignancies with an overall 5 year survival rate of 47% (cancer.org)
- Early identification of ovarian cancer significantly improves patient outcomes
- The ability to identify potentially malignant ovarian lesions by imaging is critical in early detection
- Approximately 23% of incidentally found adnexal lesions cannot be classified as benign or malignant by a single ultrasound¹
- 1. Timmerman, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ 2010;341:c6839



Background


- Cystic ovarian lesions >5cm in size¹, or with thick, avascular septations and/or soft tissue components are considered sonographically indeterminate^{2,3}
- The incidence of ovarian cancer in ultrasound indeterminate lesions is not well documented

- 1. Ekerhovd E, et al. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography. Am J Obstet Gynecol 2001; 184:48-54.
- 2. Timmerman, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before suragery. BMJ 2010;341:c6839.
- 3. Levine D, Brown DL, Andreotti RF, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US SRU consensus conference statement. Ultrasound quarterly 2010; 26:121-131.




Methods: Subjects

- IRB-approved, HIPAA compliant retrospective imaging review study
- General low-risk outpatients from multiple academic centers: UW, UM, Duke
 - Non-pregnant
 - Post-menarchal women of any age who underwent a transvaginal ultrasound exam between October 2010 and November 2011




Methods: Procedures

- Review of transvaginal US exams from October 2010 to June 2011:
 - Cystic ovarian lesions were identified and a fellowshiptrained abdominal radiologist reviewed the US images, recording:
 - Cyst type
 - Number and thickness of septations
 - Number and greatest size of soft tissue nodules
 - Presence or absence of flow in any soft tissue component
- Clinical and imaging records were reviewed to document follow-up and outcome:
 - Patients were included if one of the following was true:
 - Resolution or decrease in lesion size on follow-up imaging
 - Surgical pathology was available
 - Normal pelvic exam ≥2 years from the baseline study was documented




Methods: Inclusion/Exclusion

- Included cystic lesions:
 - − ≥5 cm
 - Thick, avascular septations
 - Avascular soft tissue components
 - Atypical hemorrhagic cysts, atypical dermoids, atypical endometriomas
- Excluded lesions:
 - Ovarian lesions with blood flow in the internal soft tissue components
 - Classic appearing lesions ≤5cm in diameter
 - Simple cysts, endometriomas, hemorrhagic cysts, dermoids
 - Solid lesions



Lesion selection: Size ≥ 5cm

- A 7.2 cm simple left ovarian cyst in a 54 year-old, which enlarged slowly on follow-up imaging
- Pathology showed benign serous cystadenoma
- Lesions ≥5cm are considered incompletely evaluated by ultrasound, and therefore indeterminate¹




1. Ekerhovd E, et al. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography. Am J Obstet Gynecol 2001; 184:48-54.

Lesion selection: Thick septation (>3mm) without blood flow

 A 38 year-old asymptomatic female with a 5cm complex adnexal lesion, with a single, avascular, thick septation (yellow arrow)

 Pathology showed mucinous cystadenoma



Lesion selection: Soft tissue nodule without blood flow

 A 2.4 cm complex left ovarian cyst with a 4 mm avascular soft tissue nodule (yellow arrow) in a 52 yearold


 Pathology showed serous cystadenofibroma



Lesion selection: Atypical dermoid

 A 31 year-old female with a 6 cm complex lesion, with atypical features for dermoid (dots, no dashes) and a septation (yellow arrow)


 Pathology showed mucinous cystadenocarcinoma



Lesion selection: Atypical endometrioma


48 year-old asymptomatic perimenopausal female with a 5cm complex adnexal lesion: homogenous echoes, similar to an endometrioma, however, there is also a thick septation (blue arrows) and apparent soft tissue nodules (yellow arrows), with no internal blood flow

 Pathology showed endometroid adenocarcinoma




Results: Patients

- Mean age of 41.3 +/- 14 years
 - Age range: 14-85 years
- Menstrual status:
 - 72.5% pre-menopausal
 - 23.2% post-menopausal
 - 4.3% unknown menstrual status
- Follow-up inclusion:
 - 50.4% by imaging
 - 47.4% by pathology
 - 2.2% by clinical follow-up




Results: Lesion types by imaging

- 856 total cystic ovarian lesions
- 27.2% indeterminate lesions (n=233)
 - 39.9% complex cysts
 - 29.2% simple cysts
 - 11.6% classic hemorrhagic cyst ≥5cm
 - 11.2% atypical hemorrhagic cyst
 - 3.4% classic endometrioma ≥5cm
 - 1.7% classic dermoid ≥5cm
 - 1.7% atypical dermoid
 - 1.3% atypical endometrioma




Results: Lesions



- Non-neoplastic, benign (n=165) Endometriomas, follicular and hemorrhagic cysts
- Neoplastic, benign (n=53)
 Cystadenomas, cystadenofibromas,
 dermoids/mature teratomas
- Malignant (n=8)
 Borderline, low-grade and high-grade

Results: Benign Non-neoplastic Lesions



Endometrioma (n=19)


■ Follicular cyst (n=14)

■ Hemorrhagic cyst (n=11)

Other* (n=4)

*One each of stromal hyperplasia, peritoneal inclusion cyst, tubo-ovarian abscess, and xanthogranulomatous inflammation


Results: Benign Neoplastic Lesions*



one contained a focus of atypia

**One serous cystadenoma lesion contained a synchronous Brenner tumor and

Results: Malignant Lesions



■ Non-invasive tumors (n=3)

Borderline tumors: 2/3 were bilateral lesions in the same patient

■ Invasive tumor (n=5)

1 metastatic adenocarcinoma from colon primary

1 low grade mucinous adenocarcinoma

1 low grade serous carcinoma


1 clear cell carcinoma

1 adenocarcinoma with both serous and clear cell features

- 5/8 (62.5%) patients with malignant lesions were pre-menopausal
- 3/8 (37.5%) patients with malignant lesions were post-menopausal


Discussion

- Of the 226 included indeterminate adnexal lesions, 73% were non-neoplastic, 23.5% were benign ovarian neoplasms, and 3.5% were malignant ovarian neoplasms
 - There is a high percentage of pre-menopausal women in our study population (72.1%), which may account for the high incidence of nonneoplastic lesions




Discussion

- Endometriomas were the most common benign, non-neoplastic lesions identified in this study
- Serous cystadenoma was the most common benign neoplasm, followed by mature teratoma
- Of the malignant lesions, 3 were borderline tumors and 4 lesions were invasive cancers of ovarian origin




Limitations

- Retrospective study
- Low-risk outpatient population with a high percentage of pre-menopausal patients
- Small number of malignancies



Summary

- The incidence of indeterminate ovarian lesions in our population was 27%
- Benign lesions accounted for a significant proportion of these lesions (96%)
- Malignancy was identified in a small but significant proportion of patients (4%)
- Our findings highlight the importance of follow-up of sonographically indeterminate ovarian lesions
 - Follow-up by US or MRI, or surgical consultation can be considered based on the clinical picture
- Follow-up of these lesions is a future area of research, as currently there are no evidence-based guidelines to suggest which method of follow up is best



Thank you for your attention!

Questions or comments?

Please feel free to contact us at:

acahoon@uwhealth.org

Or

esadowski@uwhealth.org

